These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37676213)

  • 1. Short-Term Changes in Peak VO
    Lorenzo M; Jacobs-Cachá C; Palau P; Amiguet M; Seller J; Núñez E; Espriella R; Górriz JL; Miñana G; Sanchis J; Bayés-Genis A; Soler MJ; Packer M; Núñez J;
    JACC Heart Fail; 2023 Nov; 11(11):1611-1622. PubMed ID: 37676213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction.
    Lorenzo M; Miñana G; Palau P; Amiguet M; Seller J; Garcia Pinilla JM; Domínguez E; Villar S; DE LA Espriella R; Núñez E; Górriz JL; Valle A; Bodí V; Sanchis J; Bayés-Genis A; Núñez J;
    J Card Fail; 2023 May; 29(5):849-854. PubMed ID: 36871614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO
    Palau P; Amiguet M; Domínguez E; Sastre C; Mollar A; Seller J; Garcia Pinilla JM; Larumbe A; Valle A; Gómez Doblas JJ; de la Espriella R; Miñana G; Mezcua AR; Santas E; Bodí V; Sanchis J; Pascual-Figal D; Górriz JL; Baýes-Genís A; Núñez J;
    Eur J Heart Fail; 2022 Oct; 24(10):1816-1826. PubMed ID: 35604416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
    Docherty KF; Welsh P; Verma S; De Boer RA; O'Meara E; Bengtsson O; Køber L; Kosiborod MN; Hammarstedt A; Langkilde AM; Lindholm D; Little DJ; Sjöstrand M; Martinez FA; Ponikowski P; Sabatine MS; Morrow DA; Schou M; Solomon SD; Sattar N; Jhund PS; McMurray JJV;
    Circulation; 2022 Sep; 146(13):980-994. PubMed ID: 35971840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction.
    Miñana G; de la Espriella R; Palau P; Amiguet M; Seller J; García Pinilla JM; Núñez E; Górriz JL; Valle A; Sanchis J; Bayés-Genís A; Núñez J;
    Rev Esp Cardiol (Engl Ed); 2023 Oct; 76(10):783-792. PubMed ID: 36958534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.
    Lewis GD; Malhotra R; Hernandez AF; McNulty SE; Smith A; Felker GM; Tang WHW; LaRue SJ; Redfield MM; Semigran MJ; Givertz MM; Van Buren P; Whellan D; Anstrom KJ; Shah MR; Desvigne-Nickens P; Butler J; Braunwald E;
    JAMA; 2017 May; 317(19):1958-1966. PubMed ID: 28510680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction-a substudy of the DAPA-VO
    Mora-Fernández C; Pérez A; Mollar A; Palau P; Amiguet M; de la Espriella R; Sanchis J; Górriz JL; Soler MJ; Navarro-González JF; Núñez J; ;
    Front Cardiovasc Med; 2023; 10():1242108. PubMed ID: 37745119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
    Docherty KF; Jhund PS; Claggett B; Ferreira JP; Bengtsson O; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; McMurray JJV;
    JAMA Cardiol; 2021 Nov; 6(11):1298-1305. PubMed ID: 34319398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
    van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
    Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction.
    Amiguet M; Palau P; Domínguez E; Seller J; Pinilla JMG; de la Espriella R; Miñana G; Valle A; Sanchis J; Górriz JL; Bayés-Genís A; ; Núñez J
    Sci Rep; 2023 Jun; 13(1):10591. PubMed ID: 37391470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial.
    Ambrosy AP; Lewis GD; Malhotra R; Jones AD; Greene SJ; Fudim M; Coles A; Butler J; Sharma A; Hernandez AF; Mentz RJ
    J Cardiovasc Med (Hagerstown); 2019 Apr; 20(4):223-225. PubMed ID: 30540649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
    Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
    JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
    Berg DD; Docherty KF; Sattar N; Jarolim P; Welsh P; Jhund PS; Anand IS; Chopra V; de Boer RA; Kosiborod MN; Nicolau JC; O'Meara E; Schou M; Hammarstedt A; Langkilde AM; Lindholm D; Sjöstrand M; McMurray JJV; Sabatine MS; Morrow DA
    Circulation; 2022 Jan; 145(3):158-169. PubMed ID: 34743554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
    Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
    Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
    Borlaug BA; Reddy YNV; Braun A; Sorimachi H; Omar M; Popovic D; Alogna A; Jensen MD; Carter R
    Circulation; 2023 Sep; 148(10):834-844. PubMed ID: 37534453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
    Berg DD; Jhund PS; Docherty KF; Murphy SA; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sjöstrand M; Solomon SD; McMurray JJV; Sabatine MS
    JAMA Cardiol; 2021 May; 6(5):499-507. PubMed ID: 33595593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
    Shen L; Kristensen SL; Bengtsson O; Böhm M; de Boer RA; Docherty KF; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez MFA; O'Meara E; Nicolau JC; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV
    JACC Heart Fail; 2021 Apr; 9(4):254-264. PubMed ID: 33549554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
    Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
    Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.